Schedule Update - effective 1 October 2008 (text extract)

This is the text extract for Schedule Update - effective 1 October 2008, browse documents here.

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 October 2008 Cumulative for September and October 2008 Section H cumulative for August, September and October 2008

Contents

Summary of PHARMAC decisions effective 1 October 2008 .......................... 3 New Treatment for Benign Prostatic Hyperplasia........................................... 5 CD Dispensing ............................................................................................... 5 Tender Notification Corrections ..................................................................... 6 Tender News .................................................................................................. 6 Looking Forward ........................................................................................... 6 Sole Subsidised Supply products cumulative to September 2008.................. 7 New Listings ................................................................................................ 14 Changes to Restrictions ............................................................................... 17 Changes to Subsidy and Manufacturer’s Price............................................. 21 Changes to Brand Name ............................................................................. 25 Changes to Description ............................................................................... 25 Changes to General Rules............................................................................ 26 Changes to Sole Subsidised Supply ............................................................. 26 Delisted Items ............................................................................................. 27 Items to be Delisted .................................................................................... 28 Section H changes to Part II ........................................................................ 30 Section H changes to Part IV ....................................................................... 36 Index ........................................................................................................... 37

Summary of PharmaC decisions

effeCtIve 1 oCtober 2008 New listings (pages 14 to 15) • Aminoacid formula without phenylalanine (Lophlex LQ) Liquid berry 62.5 ml OP and 125 ml OP, liquid citrus 62.5 ml OP and 125 ml OP and liquid orange 62.5 ml OP and 125 ml OP • Cefazolin sodium (Hospira) inj 500 mg and 1 g • Clozapine (Clopine) tabs 25 mg, 50 mg, 100 mg and 200 mg – 100 tablet bottle pack • Finasteride (Fintral) tab 5 mg – Special Authority – Retail pharmacy • Flucloxacillin sodium (Flucloxin) inj 250 mg, 500 mg and 1 g – 10 inj packs • Paediatric oral feed 1kcal/ml (Pediasure) liquid strawberry 200ml OP and liquid chocolate 200 ml OP – Special Authority – Hospital pharmacy [HP3] • Phenyl free pasta (Loprofin) animal shapes 500 g OP, lasagne 250 g OP, penne 500 g OP and macaroni 250 g OP – Special Authority – Hospital pharmacy [HP3] • Risperidone (Ridal) tabs tab 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg – 60 tablet bottle pack • Simvastatin (Simvarex) tab 80 mg Changes to restriction (page 17) • Diphenoxylate hydrochloride with atropine sulphate (Diastop) tab 2.5 mg with atropine sulphate 25 µg – addition of Section 29 criteria • Methadone hydrochloride (AFT) inj 10 mg per ml, 1 ml – removal of Section 29 • Risperidone (Risperdal) oral liquid 1 mg per ml – removal of OP Decreased subsidy (pages 21 to 23) • Clopidogrel (Plavix) tab 75 mg • Ketoconazole (Ketopine) shampoo 2% • Mask for spacer device (Foremount Child’s Silicone Mask) size 2 • Paclitaxel (Baxter) inj 1 mg for ECP • Peak flow meter (Breath-Alert) low range and normal range • Poloxamer (Coloxyl) oral drops 10% • Spacer device (Space Chamber) 230 ml (autoclavable) Increased subsidy (pages 21 to 23) • Acetazolamide (Diamox) tab 250 mg • Aminoacid formula without phenylalanine (Phlexy 10, Minaphlex, Phlexy 10, XP Analog LCP, XP Maxamaid, XP Maxamum, Easiphen Liquid and Easiphen)

Summary of PharmaC decisions – effective 1 october 2008 Increased subsidy (pages 21 to 23) (continued) • Atropine sulphate (Atropt) eye drops 1% • Benzylpenicillin sodium (Penicillin G) (Sandoz) inj 1 mega u • Bezafibrate (Fibalip) tab 200 mg • Calcitonin (Miacalcic) inj 100 iu per ml, 1 ml • Clonazepam (Paxam) tab 500 µg and 2 mg • Erythromycin ethyl succinate (E-Mycin) grans for oral liq 200 mg per 5 ml and 400 mg per 5 ml • Hyoscine N-Butylbromide (Gastrosoothe) tab 10 mg • Hyoscine N-Butylbromide (Buscopan) inj 20 mg, 1 ml • Mebeverine (Colofac) tab 135 mg • Methyldopa (Prodopa) tab 125 mg, 250 mg and 500 mg • Nortriptyline (Norpress) tab 10 mg and 25 mg • Nystatin (Nilstat) oral liq 100,000 u per ml • Potassium bicarbonate (Phosphate-Sandoz) tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg • Prednisone (Apo-Prednisone) tab 1 mg and 2.5 mg • Procaine penicillin (Cilicaine) inj 1.5 mega u • Tar with triethanolamine lauryl sulphate and fluorescein (Pinetarsol) soln 500 ml and 1,000ml • Temazepam (Normison) tab 10 mg • Triamcinolone acetonide (Aristocort) crm 0.02% and oint 0.02% • Trimethoprim (TMP) tab 300 mg • Vancomycin hydrochloride (Pacific) inj 50 mg per ml, 10 ml • Zinc sulphate (Zincaps) cap 220 mg

Pharmaceutical Schedule - Update News

New Treatment for Benign Prostatic Hyperplasia

PHARMAC is to begin funding a treatment for benign prostatic hyperplasia (BPH). From 1 October, finasteride (Fintral) 5 mg tablets will be funded for BPH with Special Authority criteria. BPH is relatively common, particularly in men aged over 50. It is the most prevalent urological disease in men, and causes an enlarged prostate that interferes with urine flow, and can interfere with daily activities. Finasteride is an off-patent drug that has been sourced through the PHARMAC tender.

Finasteride is being listed under Special Authority for men who are unable to be successfully treated with alpha blockers.

CD Dispensing

In the rare situation where the pharmacist does not have the stock to fill the first dispensing of a Class B Controlled Drug, it is acceptable, as stated in the Pharmacy Procedures Manual, to claim an extra dispensing fee to cover the amount due from the first dispensing. This applies only to the initial dispensing of a Class B Controlled drug. For example, if a prescription for 60 morphine long-acting 60 mg tablets, dispensed 20 + 20 + 20, is received by a pharmacy and only 10 tablets are in stock the prescription can be dispensed and claimed as 10 + 10 + 20 + 20. This includes situations where both dispensings of 10 are dispensed on the same day. Sufficient stock should be held for the subsequent dispensings of 20 so only one dispensing fee per 20 would be paid. This applies only to prescriptions and not PSO or BSO supplies.

Tender Notification Corrections

Amendments to the August Tender Notification dated 29 August 2008: Flucloxacillin sodium Douglas’ brand of flucloxacillin sodium 1 g injection will be listed fully subsidised in a pack size of 10 injections, with a new tender subsidy of $14.00 per pack not $7.00 as included in the notification fax. Mebendazole Multichem’s brand of mebendazole 100 mg tablets in a pack size of 24 tablets will be listed in Section H from 1 March 2009; and the 1% DV limit and DV Pharmaceutical (Vermox) will apply from 1 May 2009. This information was omitted from the notification fax. Nortriptyline hydrochloride Pacific’s brand of nortriptyline hydrochloride 25 mg tablets will continue to be supplied in a bottle of 250 tablets not in blisters as included in the notification fax.

tender News

Sole Subsidised Supply changes – effective 1 November 2008

Chemical Name Amantadine hydrochloride Cefuroxime sodium Cefuroxime sodium Chlorhexidine gluconate Dipyridamole Glyceryl trinitrate Presentation; Pack size Cap 100 mg; 60 cap Inj 1.5 g; 1 inj Inj 750 mg; 5 inj Soln 4%; 500 ml Tab long-acting 150 mg; 60 tab Oral pump spray 400 µg per dose; 250 dose Sole Subsidised Supply brand (and supplier) Symmetrel (Novartis New Zealand Limited) Zinacef (GlaxoSmithKline) Zinacef (GlaxoSmithKline) Orion (Orion Laboratories Pty Ltd) Pytazen SR (Douglas Pharmaceuticals Ltd) Nitrolingual Pumpspray (Douglas Pharmaceuticals Ltd)

Looking forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule. Possible decisions for implementation 1 November 2008 • Bicalutamide (Biclax) tab 50 mg – new listing with Special Authority criteria • Insulin lispro 25% with insulin lispro protamine suspension 75% (Humalog Mix 25) soln for inj 100 u per ml, 3 ml – new listing • Insulin lispro 50% with insulin lispro protamine suspension 50% (Humalog Mix 50) soln for inj 100 u per ml, 3 ml – new listing • Leflunomide tab 10 mg, 20 mg and 100 mg – removal of Special Authority criteria • Quinapril (Accupril) tab 5 mg, 10 mg and 20 mg – decreased subsidy

Sole Subsidised Supply Products – cumulative to October 2008

Generic Name

Aciclovir Alprazolam

Presentation

Tab dispersible 200 mg Tab dispersible 400 mg Tab 250 µg Tab 500 µg Tab 1 mg Inj 10 mg per ml, 1 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Tab 100 mg Tab dispersible 300 mg Tab 100 mg Tab 50 mg & 100 mg Inj 600 µg, 1 ml Inj 1200 µg, 1 ml Tab 500 mg Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg Scalp app 0.1% Tab 5 mg Eye drops 0.2% Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml Lotion BP Crm, aqueous, BP Cap 0.25 µg & 0.5 µg Inj 50 mg Tab 12.5 mg, 25 mg & 50 mg Cap 250 mg Grans for oral liq 125 mg per 5 ml Crm BP Eye drops 0.5% Eye oint 1% Handrub 1% with ethanol 70% Mouthwash 0.2% Tab 25 mg Tab 250 mg Grans for oral liq 125 mg per 5 ml Crm 0.05%

Brand Name Expiry Date*

Lovir Lovir Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam Mayne Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin Apo-Ascorbic Acid Ethics Aspirin Ethics Aspirin EC Loten AstraZeneca AstraZeneca Arrow-Azithromycin Alanase Alanase Beta Scalp Lax-Tab AFT Marcain Isobaric Marcain Heavy ABM ABM Calcitriol-AFT Calcium Folinate Ebewe Apo-Captopril Ranbaxy Cefaclor Ranbaxy Cefaclor PSM Chlorsig Chlorsig Orion Orion Hygroton Klamycin Klacid Dermol 2009 2010

Apomorphine hydrochloride Amoxycillin

2009 2010 2009 2009 2010 2009 2009 2009 2009 2009 2010 2011 2010 2009 2009 2011 2010 2010 2010 2009 2009 2009 2010 2009

Ascorbic acid Aspirin Atenolol Atropine sulphate Azithromycin Beclomethasone dipropionate Betamethasone valerate Bisacodyl Brimonidine tartrate Bupivicaine hydrochloride Calamine Calcitriol Calcium folinate Captopril Cefaclor monohydrate Cetomacrogol Chloramphenicol Chlorhexidine gluconate Chlorthalidone Clarithromycin Clobetasol propionate

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 7

Sole Subsidised Supply Products – cumulative to October 2008

Generic Name

Clotrimazole Codeine phosphate Colchicine Colestipol hydrochloride Colistin sulphomethate Compound electrolytes Cyclizine hydrochloride Cyclophosphamide Cyproterone acetate Dantrolene sodium Desferrioxamine mesylate Desmopressin Dexamethasone sodium phosphate Dexamphetamine sulphate Dextrose Dextrose with electrolytes

Presentation

Crm 1% Vaginal crm 1% with applicator(s) Tab 15 mg, 30 mg & 60 mg Tab 500 µg Sach 5 g Inj 150 mg Powder for soln for oral use Tab 50 mg Tab 50 mg Tab 50 mg Cap 25 mg & 50 mg Inj 500 mg Nasal spray 10 mcg per dose Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml Tab 5 mg Inj 50%, 10 ml Oral soln with electrolytes

Brand Name Expiry Date*

Clomazol Clomazol PSM Colgout Colestid Colistin-Link Enerlyte Nausicalm Cycloblastin Siterone Dantrium Mayne Desmopressin-PH&T Mayne PSM Biomed Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit Voltaren Ophtha Voltaren Voltaren Voltaren Voltaren Voltaren Apo-Diclo Apo-Diclo SR Videx EC Apo-Doxazosin AFT m-Enalapril Mayne Cafergot New Zealand Medical and Scientific 2011 2010 2010 2010 2010 2010 2010 2009 2010 2009 2009 2010 2011 2009 2010 2011 2010

Dicloflenac sodium

Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg Suppos 25 mg Suppos 50 mg Suppos 100 mg Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg Cap 125 mg, 200 mg, 250 mg & 400 mg Tab 2 mg & 4 mg Oint BP Tab 5 mg, 10 mg & 20 mg Inj 500 µg per ml, 1 ml Tab 1 mg with caffeine 100 mg Tab 10 µg

2011

2009 2009 2010 2011 2009 2009 2009 2009

Didanosine (DDI) Doxazosin mesylate Emulsifying ointment Enalapril Ergometrine maleate Ergotamine tartrate with caffeine Ethinyloestradiol

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 8

Sole Subsidised Supply Products – cumulative to October 2008

Generic Name

Ethinyloestradiol with norethisterone

Presentation

Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab Cap 50 mg & 100 mg Oral liq 150 mg per 5 ml Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap 50 mg Cap 150 mg Cap 200 mg Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg Eye drops 0.1% Cap 20 mg Tab disp 20 mg, scored Tab 0.8 mg & 5 mg Crm 2% & Oint 2% Inj 40 mg per ml, 2 ml Tab 80 mg Tab 5 mg TDDS 5 mg TDDS 10 mg Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml Inj 10 iu per ml, 5 ml Crm 1% Tab 5 mg & 20 mg Rectal foam 10%, CFC-Free Scalp lotn 0.1% Lotn 1% with wool fat hydrous 3% and mineral oil Oral liq 100 mg per 5 ml, 200 ml

Brand Name Expiry Date*

Brevinor 21 Brevinor 1/21 Brevinor 1/28 Vepesid Ferodan Staphlex AFT AFT Pacific Pacific Pacific Ultraproct Ultraproct 2009 2010 2009 2010

Etoposide Ferrous sulphate Flucloxacillin sodium

Fluconazole

2011

Fluocortolone caproate with fluocortolone pivalate and cinchocaine

2010

Fluorometholone Fluoxetine hydrochloride Folic Acid Fusidic acid Gentamicin sulphate Gliclazide Glipizide Glyceryl trinitrate Haloperidol

Flucon Fluox Fluox Apo-Folic Acid Foban Pfizer Apo-Gliclazide Minidiab Nitroderm TTS 5 Nitroderm TTS 10 Serenace Serenace Serenace AstraZeneca PSM Douglas Colifoam Locoid DP Lotn HC Fenpaed

2009 2010 2009 2010 2009 2011 2011 2011 2010 2009 2009 2011 2009 2009 2010 2011 2010

Heparinised saline Hydrocortisone Hydrocortisone acetate Hydrcortisone butyrate Hydrocortisone with wool fat and mineral oil Ibuprofen

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 9

Sole Subsidised Supply Products – cumulative to October 2008

Generic Name

Imipramine hydrochloride Indapamide Ipratropium bromide

Presentation

Tab 10 mg & 25 mg Tab 2.5 mg Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml Tab long-acting 60 mg Cap 10 mg Cap 20 mg Cap 100 mg Oral liq 10 g per 15 ml Eye drops 0.25% & 0.5% Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml Crm 2.5% with prilocaine 2.5%; 30 g OP Crm 2.5% with prilocaine 2.5%; 5 g Tab 5 mg, 10 mg & 20 mg Tab 2 mg Tab 10 mg Oral liq 1 mg per ml

Brand Name Expiry Date*

Tofranil Napamide Apo-Ipravent Ipratripium Steri-Neb Ipratripium Steri-Neb Duride Isotane 10 Isotane 20 Sporanox Duphalac Betagan Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250 Xylocaine Xylocaine Xylocaine EMLA EMLA Arrow-Lisinopril Nodia Loraclear Hayfever Relief Lorapaed Ativan Mayne Derbac M A-Lices Ludiomil Provera Pentasa Arrow-Metformin Methatabs AFT Methoblastin 2009 2010 2010 2010 2009 2009 2010

Isosorbide mononitrate Isotretinoin Itraconazole Lactulose Levobunolol Levodopa with benserazide

2009 2009 2010 2010 2010 2009

Lignocaine hydrochloride

Lignocaine with prilocaine

2010

Lisinopril Loperamide hydrochloride Loratadine

Lorazepam Magnesium sulphate Malathion Maldison Maprotiline hydrochloride Medroxyprogesterone acetate Mesalazine Metformin hydrochloride Methadone hydrochloride Methotrexate

Tab 1 mg & 2.5 mg Inj 49.3% Liq 0.5% Shampoo 1% Tab 25 mg & 75 mg Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg Enema 1 g per 100 ml Tab 500 mg & 850 mg Tab 5 mg Powder 1 g Tab 2.5 mg & 10 mg

2009 2009 2010 2010 2009 2010 2009 2009 2010 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 10

Sole Subsidised Supply Products – cumulative to October 2008

Generic Name

Methylphenidate hydrochloride

Presentation

Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg Tab 4 mg & 100 mg Crm 0.1% and oint 0.1% Inj 40 mg per ml, 1 ml Inj 40 mg per ml with lignocaine 1 ml Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g Inj 5 mg per ml, 2 ml Tab long-acting 200 mg Cap 250 mg Crm 2% Tab 2.5 mg & 5 mg Tab 200 µg Tab 150 mg & 300 mg Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml Inj 10 mg per ml, 1 ml Inj 30 mg per ml, 1 ml Inj 5 mg per ml, 1 ml Inj 15 mg per ml, 1 ml Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg Tab immediate release 10 mg & 20 mg Inj 80 mg per ml, 1.5 ml & 5 ml Tab 40 mg & 80 mg Tab 50 mg Tab 250 mg Tab 500 mg Tab 275 mg Inj 2.5 mg per ml, 1 ml Oral suspension 10 mg per ml Tab 50 mg & 500 mg Tab long-acting 20 mg

Brand Name Expiry Date*

Rubifen SR Rubifen Rubifen Medrol Advantan Depo-Medrol Depo-Medrol with Lidocaine Solu-Medrol Solu-Medrol Solu-Medrol Pfizer Slow-Lopresor Metopirone Multichem Gutron Cytotec Apo-Moclobemide RA-Morph RA-Morph RA-Morph RA-Morph Mayne Mayne Mayne Mayne m-Eslon Sevredol Mayne Apo-Nadolol ReVia Noflam 250 Noflam 500 Sonaflam AstraZeneca Viramune Suspension Apo-Nicotinic Acid Nyefax Retard 2009 2010 2010 2009 2010 2010 2009 2009 2009 2009

Methylprednisolone Methylprednisolone aceponate Methylprednisolone acetate Methylprednisolone acetate with lignocaine Methylprednisolone sodium succinate Metoclopramide hydrochloride Metoprolol tartrate Metyrapone Miconazole nitrate Midodrine Misoprostol Moclobemide Morphine hydrochloride

2009 2009 2011 2011 2009

2011 2009 2009 2011 2009 2009 2009 2009

Morphine sulphate

2011 2009

Morphine tartrate Nadolol Naltrexone hydrochloride Naproxen Naproxen sodium Neostigmine Nevirapine Nicotinic acid Nifedipine

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 11

Sole Subsidised Supply Products – cumulative to October 2008

Generic Name

Norethisterone Nystatin

Presentation

Tab 5 mg Tab 350 µg Cap 500,000 u Tab 500,000 u Vaginal crm 100,000 u per 5 g with applicators Tab 4 mg & 8 mg Tab disp 4 mg & 8 mg Tab 5 mg Oral liq 5 mg per 5 ml Inj 10 mg per ml, 1 ml and 2 ml Oral liq 5 mg per 5 ml Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml Tab 20 mg Tab 40 mg

Brand Name Expiry Date*

Primolut N Noriday 28 Nilstat Nilstat Nilstat Zofran Zofran Zydis Apo-Oxybutynin Apo-Oxybutynin OxyNorm OxyNorm Syntocinon Syntocinon Syntometrine Pamisol Pamisol Pamisol Dr Reddy’s Pantoprazole Dr Reddy’s Pantoprazole Lacri-Lube Loxamine Permax Permax Pexsig AFT AFT Cilicaine VK Cilicaine VK Prefrin Span-K Apo-Prazo MDS Quick Card Apo-Pyridoxine Q 200 Q 300 Peptisoothe Mycobutin 2011 2009 2010 2009 2010 2010 2010 2009

Ondansetron Oxybutynin Oxycodone hydrochloride Oxytocin

Pamidronate disodium

2011

Pantoprazole

2010

Paraffin liquid with soft white paraffin Paroxetine hydrochloride Pergolide Perhexiline maleate Phenoxymethylpenicillin (Penicillin V)

Eye oint with soft white paraffin Tab 20 mg Tab 0.25 mg Tab 1 mg Tab 100 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg Eye drops 0.12% Tab long-acting 600 mg Tab 1 mg, 2 mg & 5 mg Cassette Tab 50 mg Tab 200 mg Tab 300 mg Oral liq 150 mg per 10 ml Cap 150 mg

2010 2010 2011 2009 2010

Phenylephrine hydrochloride Potassium chloride Prazosin hydrochloride Pregnancy tests - HCG urine Pyridoxine hydrochloride Quinine sulphate Ranitidine hydrochloride Rifabutin

2010 2009 2010 2009 2009 2009 2010 2010

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 12

Sole Subsidised Supply Products – cumulative to October 2008

Generic Name

Roxithromycin Salbutamol

Presentation

Tab 150 mg & 300 mg Nebuliser soln 1 mg per ml, 2.5 ml Nebuliser soln 2 mg per ml, 2.5 ml Oral liq 2 mg per 5 ml Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg Tab 5 mg Inj 0.9%, 5 ml & 10 ml Grans eff 4 g sachets Nasal spray 4% Tab 500 mg Tab EC 500 mg Liq Tab 250 mg Inj long-acting 100 mg per ml, 10 ml Inj 250 mcg Inj 1 mg per ml, 1 ml Eye drops 0.25% Eye drops 0.5% Tab 10 mg Tab 50 mg 0.1% in Dental Paste USP Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g Cap 300 mg Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml Tab (BPC cap strength) Tab, strong, BPC Purified for injection 20 ml

Brand Name Expiry Date*

Arrow-Roxithromycin Asthalin Asthalin Salapin Duolin Apo-Selegiline AstraZeneca Ural Rex Salazopyrin Salazopyrin EN Midwest Apo-Terbinafine Depo-Testosterone Synacthen Synacthen Depot Apo-Timop Apo-Timop Apo-Timol Apo-Thiamine Oracort Kenacomb 2009 2009 2010 2009 2009 2009 2010 2009 2009 2010 2011 2011 2011 2011 2009 2009 2011 2009

Salbutamol with ipratropium bromide Selegiline hydrochloride Sodium chloride Sodium citro-tartrate Sodium cromoglycate Sulphasalazine Syrup (pharmaceutical grade) Terbinafine Testosterone cypionate Tetracosactrin Timolol maleate

Thiamine hydrochloride Triamcinolone acetonide Triamcinolone acetonide with gramicidin, neomycin and nystatin Ursodeoxycholic acid Vincristine sulphate Vitamins Vitamin B complex Water October changes in bold type.

Actigall Mayne Mayne Healtheries Apo-B-Complex Multichem

2011 2009 2009 2009 2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated. 13

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings

Effective 1 October 2008

50 77 SIMVASTATIN - see prescribing guidelines on the preceding page ❋ Tab 80 mg ................................................................................ 3.18 30 ✔ SimvaRex

FINASTERIDE Special Authority see SA0928 – Retail Pharmacy Tab 5 mg ................................................................................ 19.20 30 ✔ Fintral ➽ SA0928 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both: 1 Patient has symptomatic benign prostatic hyperplasia; and 2 Either: 2.1 The patient is intolerant of non-selective alpha blockers or these are contraindicated; or 2.2 Symptoms are not adequately controlled with non-selective alpha blockers Note: patients with enlarged prostates are the appropriate candidates for therapy with finasteride. CEFAZOLIN SODIUM – Hospital Pharmacy [HP3] – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patients and the prescription is endorsed accordingly. Inj 500 mg ................................................................................ 5.00 5 ✔ Hospira Inj 1 g ....................................................................................... 8.00 5 ✔ Hospira FLUCLOXACILLIN SODIUM Inj 250 mg ................................................................................ 9.00 Inj 500 mg .............................................................................. 10.40 Inj 1 g – Up to 5 inj available on a PSO..................................... 14.00 CLOZAPINE – Hospital pharmacy [HP4] – Specialist prescription Tab 25 mg .............................................................................. 35.20 Tab 50 mg .............................................................................. 45.60 Tab 100 mg ............................................................................ 91.20 Tab 200 mg .......................................................................... 145.92 RISPERIDONE Retail Pharmacy – Specialist Tab 0.5 mg ............................................................................. 15.60 10 10 10 100 100 100 100 60

✔ Flucloxin ✔ Flucloxin ✔ Flucloxin

119

✔ Clopine ✔ Clopine ✔ Clopine ✔ Clopine ✔ Ridal

120 173

PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see SA0896 – Hospital Pharmacy [HP3] Liquid (strawberry) .................................................................... 1.07 200 ml OP ✔ Pediasure Liquid (chocolate) ..................................................................... 1.07 200 ml OP ✔ Pediasure PHENYL FREE PASTA – Special Authority see SA0733 – Hospital Pharmacy [HP3] Animal shapes......................................................................... 11.91 500 g OP ✔ Loprofin Lasagne .................................................................................... 5.95 250 g OP ✔ Loprofin Penne...................................................................................... 11.91 500g OP ✔ Loprofin Macaroni ................................................................................... 5.32 250 g OP (5.95) Loprofin AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA0733 – Hospital Pharmacy [HP3] Liquid (berry) .......................................................................... 15.65 62.5 ml OP ✔ Lophlex LQ Liquid (berry) .......................................................................... 31.20 125 ml OP ✔ Lophlex LQ Liquid (citrus) .......................................................................... 15.65 62.5 ml OP ✔ Lophlex LQ Liquid (citrus) .......................................................................... 31.20 125 ml OP ✔ Lophlex LQ Liquid (orange) ........................................................................ 15.65 62.5 ml OP ✔ Lophlex LQ Liquid (orange) ........................................................................ 31.20 125 ml OP ✔ Lophlex LQ

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

182

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2008

29 43 INSULIN GLARGINE – Special Authority see SA0834 – Retail pharmacy ▲ nj 100 iu per ml, 3 ml disposable pen ..................................... 94.50 I 5 ✔ Lantus SoloStar

ERYTHROPOIETIN ALPHA – Special Authority SA0922 – Hospital pharmacy [HP3] Inj human recombinant 5,000 iu, pre-filled syringe ................. 243.26 6 Inj human recombinant 6,000 iu, pre-filled syringe ................. 291.92 6 CLOPIDOGREL – Special Authority see SA0867 – Retail pharmacy Tab 75 mg .............................................................................. 35.00 LOSARTAN – Special Authority see SA0911 – Retail pharmacy ❋ Tab 25 mg .............................................................................. 21.76 ATENOLOL ❋ Tab 50 mg ................................................................................ 6.50 ❋ Tab 100 mg ............................................................................ 11.30 NICOTINE – Only on a Quitcard Lozenge 1 mg ......................................................................... 11.08 Lozenge 2 mg ......................................................................... 11.08 28 30 500 500 36 36

✔ Eprex ✔ Eprex

45 55 56

✔ Apo-Clopidogrel

✔ Cozaar ✔ Pacific Atenolol ✔ Pacific Atenolol ✔ Habitrol ✔ Habitrol

IMIQUIMOD – Special Authority see SA0923 – Retail pharmacy Crm 5 % ................................................................................ 110.40 12 sachets ✔ Aldara ➽ SA0923 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid for 4 months for Applications meeting the following criteria: Either: 1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or 2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or 3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate. Note Superficial basal cell carcinoma Surgical excision remains remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance. Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears. Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma. External anogenital warts Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata). Renewal from any relevant practitioner. Approvals valid for 4 months for applications meeting the following criteria: Any of the following: 1 Inadequate response to initial treatment for anogenital warts; or 2 New confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate; or 3 Inadequate response to initial treatment for superficial basal cell carcinoma. Note Confirmation that the lesion is a superficial basal cell carcinoma should be obtained using a biopsy.

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

New Listings - effective 1 September 2008 (continued)

109 128 AMITRIPTYLINE Tab 10 mg ................................................................................ 2.77 50 ✔ Amirol

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority SA0924 – Retail Pharmacy Only on a controlled drug form Tab extended-release 18 mg .................................................... 58.96 30 ✔ Concerta Tab extended-release 27 mg .................................................... 65.44 30 ✔ Concerta Tab extended-release 36 mg .................................................... 71.93 30 ✔ Concerta Tab extended-release 54 mg .................................................... 86.24 30 ✔ Concerta ➽ SA0924 Special Authority for Subsidy Initial application only from a paediatrician, psychiatrist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following: 1 ADHD (Attention Deficit and Hyperactivity Disorder); and 2 Diagnosed according to DSM-IV or ICD 10 criteria; and 3 Either: 3.1 Applicant is a paediatrician or psychiatrist; or 3.2 Both 3.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 3.2.2 Provide name of the recommending specialist; and 4 Either: 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediaterelease or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride. Renewal only from a paediatrician, psychiatrist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both: 1 The treatment remains appropriate and the patient is benefiting from treatment; and 2 Either: 2.1 Applicant is a paediatrician or psychiatrist; or 2.2 Both: 2.2.1 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and 2.2.2 Provide name of the recommending specialist

Effective 1 August 2008

75 MEDROXYPROGESTERONE ACETATE ❋ Inj 150 mg per ml, 1ml – Up to 5 inj available on a PSO ............. 8.05 1 ✔ Depo-Provera

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions

Effective 1 October 2008

25 108 DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPHATE ❋ Tab 2.5 with atropine sulphate 25 mcg ..................................... 3.90 100 ✔ Diastop S29

METHADONE HYDROCHLORIDE a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets). d) For methadone hydrochloride oral liquid refer, page 162 Inj 10 mg per ml, 1 ml ............................................................ 52.00 10 ✔ AFT S29 RISPERIDONE Oral liquid 1 mg per ml ........................................................... 45.92 30 ml OP ✔ Risperdal

120 121

RISPERIDONE – Special Authority see SA0926 below – Retail pharmacy Subject to budgetary cap. Applications will be considered and approved subject to funding availability. Microspheres for injection 25 mg .......................................... 175.00 1 ✔ Risperdal Consta Microspheres for injection 37.5 mg ....................................... 230.00 1 ✔ Risperdal Consta Microspheres for injection 50 mg .......................................... 280.00 1 ✔ Risperdal Consta

Effective 1 September 2008

29 ACARBOSE - Special Authority see SA04900925 – Retail pharmacy ❋ Tab 50 mg .............................................................................. 22.00 90 ✔ Glucobay ❋ Tab 100 mg ............................................................................ 31.00 90 ✔ Glucobay ➽ SA08740925 Special Authority for Subsidy Initial application only from a relevant practioner specialist. Approvals valid for 2 years without renewal for applications meeting the following criteria: 1 The patient has type 2 diabetes; and 2 Either: 2.1 Metformin is not tolerated, or is contraindicated; or 2.2 The patient has not responded to the maximum appropriate dose of metformin. Any of the following: 1 Requires but is not able to tolerate metformin therapy; or 2 Requires metformin but metformin is contraindicated; or 3 Has not responded to or tolerated the maximum appropriate dose of metformin. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. ERYTHROPOIETIN ALPHA – Special Authority see SA09220626 – Hospital pharmacy [HP3] ➽ SA0626 Special Authority for Subsidy Initial application only from a renal physician. Approvals valid for 2 years for applications meeting the following criteria: All of the following: General Criteria: 1 Anaemia of end-stage renal failure (other treatable causes of anaemia being excluded); and 2 Been on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD) for at least three months; and 3 Not under under evaluation for, or awaiting, a live donor kidney transplant; and continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2008 (continued)

continued... 4 Any of the following: Specific Criteria: 4.1 Anephric; or 4.2 Dependent on regular blood transfusion (1 unit each 4-8 weeks) to maintain haemoglobin > 60g/L; or 4.3 Dependent on regular blood transfusion but cannot be transfused because of severe transfusion reactions; or 4.4 Transfusion induced haemosiderosis (clinical manifestations, serum ferritin >1500 ug/L); or 4.5 Haemoglobin < 70 g/L (mean of at least 4 haemoglobin concentrations over 4 months); or 4.6 Both: 4.6.1 Haemoglobin < 90 g/L; and 4.6.2 Either: 4.6.2.1 Heart failure (low cardiac output, LV ejection fraction <40%); or 4.6.2.2 Persistent angina Renewal only from a renal physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. ➽ SA0922 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both: 1 Both: 1.1 patient in chronic renal failure; and 1.2 Haemoglobin ≤ 100g/L; and 2 Any of the following: 2.1 Both: 2.1.1 patient is not diabetic; and 2.1.2 glomerular filtration rate ≤ 30ml/min; or 2.2 Both: 2.2.1 patient is diabetic; and 2.2.2 glomerular filtration rate ≤ 45ml/min; or 2.3 patient is on haemodialysis or peritoneal dialysis. Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment. Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy. The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over: GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l) GFR (ml/min) (female) = Estimated GFR (male) × 0.85 84 GROWTH HORMONE BIOSYNTHETIC HUMAN – Special Authority see SA0755 (addition of stat dispensing) ❋ Cartridge 16 iu per vial........................................................ 1,600.00 5 ✔ Genotropin ❋ Cartridge 36 iu per vial........................................................ 3,600.00 5 ✔ Genotropin RECOMBINANT HUMAN GROWTH HORMONE – Special Authority see SA0755 (addition of stat dispensing) ❋ Inj 5 mg ................................................................................ 300.00 1 ✔ Norditropin SimpleXx 5mg ❋ Inj 10 mg .............................................................................. 600.00 1 ✔ Norditropin SimpleXx 10mg ❋ Inj 15 mg .............................................................................. 900.00 1 ✔ Norditropin SimpleXx 15mg

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2008 (continued)

114 TOPIRAMATE – Special Authority see SA0874 – Retail pharmacy ➽ SA0874 Special Authority for Subsidy Initial application — (new patients) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both: 1 Patient has epilepsy; and 2 Either: 2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or 2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatmentwith other antiepilepsy agents. Note: “Optimal treatment with other antiepilepsy agents” is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient’s age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Initial application — (patient has had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy priorto 1 August 2007) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient hasdemonstrated a significant and sustained improvement in seizure rate or severity and or quality of life from gabapentin, topiramate,vigabatrin and or lamotrigine. Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success withanticonvulsant therapy and have assessed quality of life from the patient’s perspective. Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrateda significant and sustained improvement in seizure rate or severity and or quality of life. Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success withanticonvulsant therapy and have assessed quality of life from the patient’s perspective. If the patient had an approval for gabapentin, lamotrigine, topiramate or vigabatrin for epilepsy prior to 1 August 2007 the applicant is required to submit a fresh initial application in the first instance, not a renewal application. 120 RISPERIDONE – Retail Pharmacy – Speciaist Tab 0.5 mg ............................................................................... 5.20 Tab 1 mg ................................................................................ 30.77 Tab 2 mg ............................................................................... 61.53 Tab 3 mg ............................................................................... 92.32 Tab 4 mg ............................................................................. 123.05 Oral liquid 1 mg per ml ............................................................ 45.92 20 60 60 60 60 30 ml OP ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Ridal ✔ Risperdal ✔ Risperdal

121

RISPERIDONE – Special Authority see SA09260792 – Retail pharmacy Subject to budgetary cap. Applications will be considered and approved subject to funding availability. Microspheres for injection 25 mg........................................... 175.00 1 ✔ Risperdal Consta Microspheres for injection 37.5 mg........................................ 230.00 1 ✔ Risperdal Consta Microspheres for injection 50mg............................................ 280.00 1 ✔ Risperdal Consta ➽ SA09260792 Special Authority for Subsidy Initial application only from a psychiatrist from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has schizophrenia or other psychotic disorder; and 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and continued...

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Restrictions - effective 1 September 2008 (continued)

continued... 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months. Renewal only from a psychiatrist from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either: 1 Both: 1.1 The patient has had less than 12 months treatment with risperidone microspheres; and 1.2 There is no clinical reason to discontinue treatment; or 2 The initiation of risperidone microspheres has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone microspheres. Note: Risperidone microspheres should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone microspheres. 122 RISPERIDONE – Special Authority see SA09270794 – Retail pharmacy Orally-disintegrating tablets 0.5 mg .......................................... 21.42 Orally-disintegrating tablets 1 mg ............................................. 42.84 Orally-disintegrating tablets 2 mg ............................................. 85.71 28 28 28 ✔ Risperdal Quicklet ✔ Risperdal Quicklet ✔ Risperdal Quicklet

➽ SA09270794 Special Authority for Subsidy Initial application - (Acute situations) only from a psychiatrist from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria: Both: 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and 2 The patient is under direct supervision for administration of medicine. Initial application - (Chronic situations) only from a psychiatrist from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and 2 The patient is under direct supervision for administration of medicine. Renewal only from a psychiatrist from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both: 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and 2 The patient is under direct supervision for administration of medicine. Note: Initial prescriptions to be written by psychiatrists and subsequent prescriptions can be written by psychiatric registrars or General Practitioners. Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary. 127 METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA0908 – Retail Pharmacy Only on a controlled drug form Tab immediate-release 5 mg.................................................... 3.20 30 ✔ Rubifen Tab immediate-release 10 mg.................................................. 4.29 30 ✔ Rubifen Tab immediate-release 20 mg.................................................. 7.85 30 ✔ Rubifen Tab long acting sustained-release 20 mg ............................... 10.95 30 ✔ Rubifen SR

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price

Effective 1 October 2008

27 27 34 36 38 45 HYOSCINE N-BUTYLBROMIDE ( subsidy) ❋ Tab 10 mg ............................................................................... 1.62 ❋ Inj 20 mg, 1 ml – Up to 5 inj available on a PSO ......................... 8.04 MEBEVERINE HYDROCHLORIDE ( subsidy) ❋ Tab 135 mg ........................................................................... 18.00 POLOXAMER – Only on a prescription ( subsidy) ❋ Oral drops 10% ........................................................................ 3.78 NYSTATIN ( subsidy) Oral liq 100,000 u per ml .......................................................... 3.19 ZINC SULPHATE ( subsidy) ❋ Cap 220 mg ........................................................................... 10.00 20 5 90 30 ml OP 24 ml OP 100 ✔ Gastrosoothe ✔ Buscopan ✔ Colofac ✔ Coloxyl ✔ Nilstat ✔ Zincaps

CLOPIDOGREL – Special Authority see SA0867– Retail pharmacy ( subsidy) Tab 75 mg ............................................................................. 35.00 28 (73.38) HEPARIN SODIUM ( price) Inj 25,000 iu per ml, 0.2 ml – Hospital pharmacy [HP3]Specialist .............................................................................. 7.50 (9.50) POTASSIUM BICARBONATE – Retail pharmacy-Specialist ( subsidy) Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg ............................................... 82.50 BEZAFIBRATE ( subsidy) ❋ Tab 200 mg ............................................................................. 9.75 METHYLDOPA ( subsidy) ❋ Tab 125 mg ........................................................................... 12.00 ❋ Tab 250 mg ........................................................................... 13.10 ❋ Tab 500 mg ........................................................................... 20.85 TRIAMCINOLONE ACETONIDE ( subsidy) Crm 0.02% ................................................................................ 6.63 Oint 0.02% ................................................................................ 6.69 WOOL FAT WITH MINERAL OIL – Only on a prescription ( price) ❋ Lotn hydrous 3% with mineral oil .............................................. 1.40 (3.50) 5.60 (10.90)

Plavix

Mayne

100 90 100 100 100 100 g OP 100 g OP 250 ml OP

✔ Phosphate-Sandoz ✔ Fibalip ✔ Prodopa ✔ Prodopa ✔ Prodopa ✔ Aristocort ✔ Aristocort

49 59 65

DP Lotion 1,000 ml DP Lotion

69 ❋

TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN – Only on a prescription ( subsidy) Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium ............................................................... 2.90 500 ml ✔ Pinetarsol 5.54 1,000 ml ✔ Pinetarsol Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber. ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 October 2008 (continued)

70 KETOCONAZOLE ( subsidy) Shampoo 2% ............................................................................ 3.48 a) Maximum of 100 ml per prescription b) Only on a prescription CALCITONIN – Hospital pharmacy [HP3]-Specialist ( subsidy) ❋ Inj 100 iu per ml, 1 ml .......................................................... 110.00 PREDNISONE ( subsidy) ❋ Tab 1 mg ............................................................................... 10.68 ❋ Tab 2.5 mg ............................................................................ 12.09 ERYTHROMYCIN ETHYL SUCCINATE ( subsidy) Grans for oral liq 200 mg per 5 ml – Up to 200 ml available on a PSO ................................................................. 4.35 Grans for oral liq 400 mg per 5 ml – Up to 200 ml Available on a PSO ................................................................ 5.85 BENZYLPENICILLIN SODIUM (PENICILLIN G) ( subsidy) Inj 1 mega u – Up to 5 inj available on a PSO ........................... 10.49 PROCAINE PENICILLIN ( subsidy) Inj 1.5 mega u – Up to 5 inj available on a PSO ........................ 50.86 TRIMETHOPRIM ( subsidy) ❋ Tab 300 mg – Up to 30 tab available on a PSO .......................... 8.69 100 ml OP ✔ Ketopine

79 80 90

5 500 500

✔ Miacalcic ✔ Apo-Prednisone ✔ Apo-Prednisone

100 ml 100 ml 10 5 50

✔ E-Mycin ✔ E-Mycin ✔ Sandoz ✔ Cilicaine ✔ TMP

91 92 93 93

VANCOMYCIN HYDROCHLORIDE – Hospital pharmacy [HP3] – Subsidy by endorsement ( subsidy) Only if prescribed for a dialysis or cystic fibrosis patient or in the treatment of pseudomembranous colitis or for prophylaxis of endocarditis and the prescription is endorsed accordingly. Inj 50 mg per ml, 10 ml ............................................................ 5.04 1 ✔ Pacific NORTRIPTYLINE HYDROCHLORIDE ( subsidy) Tab 10 mg ............................................................................... 5.94 Tab 25 mg ............................................................................. 20.06 CLONAZEPAM ( subsidy) Tab 500 µg .............................................................................. 6.26 Tab 2 mg ............................................................................... 11.15 MIDAZOLAM ( price) Tab 7.5 mg – Month Restriction............................................... 10.38 (25.00) TEMAZEPAM – Month Restriction ( subsidy) Tab 10 mg ................................................................................ 0.83 PACLITAXEL – PCT only – Specialist ( subsidy) Inj 1 mg for ECP ....................................................................... 1.32 100 250 100 100 100 Hypnovel 25 1 mg ✔ Normison ✔ Baxter ✔ Norpress ✔ Norpress ✔ Paxam ✔ Paxam

110

112

125

126 136

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 October 2008 (continued)

152 MASK FOR SPACER DEVICE ( subsidy) Only on a WSO Size 2 ........................................................................................ 3.28 PEAK FLOW METER ( subsidy) Only on a WSO Low range ............................................................................... 13.75 Normal range .......................................................................... 13.75 SPACER DEVICE ( subsidy) Only on a WSO 230 ml (autoclavable) .............................................................. 11.60 ACETAZOLAMIDE ( subsidy) ❋ Tab 250 mg ........................................................................... 10.40 ATROPINE SULPHATE ( subsidy) ❋ Eye drops 1% ........................................................................... 4.40

✔ Foremount Child’s Silicone Mask

152

1 1

✔ Breath-Alert ✔ Breath-Alert

152

1 100 15 ml OP

✔ Space Chamber ✔ Diamox ✔ Atropt

156 157 182

AMINOACID FORMULA WITHOUT PHENYLALANINE – Special Authority see SA0733 – Hospital pharmacy [HP3] ( subsidy) Tabs ....................................................................................... 99.00 75 OP ✔ Phlexy 10 Sachets (pineapple/vanilla) 29 g ........................................... 330.10 30 OP ✔ Minaphlex Sachets (tropical) ................................................................. 324.00 30 ✔ Phlexy 10 Infant formula ....................................................................... 174.72 400 g OP ✔ XP Analog LCP Powder (orange) .................................................................. 221.00 500 g OP ✔ XP Maxamaid 320.00 ✔ XP Maxamum Powder (unflavoured) ........................................................... 221.00 500 g OP ✔ XP Maxamaid 320.00 ✔ XP Maxamum Liquid (forest berries) ............................................................. 30.00 250 ml OP ✔ Easiphen Liquid Liquid (tropical) ...................................................................... 30.00 250 ml OP ✔ Easiphen

Effective 1 September 2008

38 CALCIUM CARBONATE ( subsidy) ❋ Tab dispersible 2.5 g ................................................................. 4.36 IRON POLYMALTOSE ( subsidy) Inj 50 mg per ml, 2 ml ............................................................. 20.95 (29.95) 20 OP ✔ Calci-Tab Effervescent

5 Ferrosig

ERYTHROPOIETIN ALPHA – Special Authority see SA0922 – Hospital pharmacy [HP3] ( subsidy) Inj human recombinant 1,000 iu, pre-filled syringe ................... 48.68 6 ✔ Eprex Inj human recombinant 2,000 iu, pre-filled syringe ................. 120.18 6 ✔ Eprex Inj human recombinant 3,000 iu, pre-filled syringe ................. 166.87 6 ✔ Eprex Inj human recombinant 4,000 iu, pre-filled syringe ................. 193.13 6 ✔ Eprex Inj human recombinant 10,000 iu, pre-filled syringe ............... 395.18 6 ✔ Eprex

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Subsidy and Manufacturer’s Price - effective 1 September 2008 (continued)

48 POTASSIUM BICARBONATE – Retail pharmacy – Specialist ( price) Tab eff 315 mg with sodium acid phosphate with 1.937 g and sodium bicarbonate 350 mg ................................................ 75.00 (82.50) PHENTOLAMINE MESYLATE ( price) ❋ Inj 10 mg per ml, 1 ml ............................................................. 17.97 (31.65) NITROFURANTOIN ( subsidy) ❋ Tab 50 mg .............................................................................. 17.90 ❋ Tab 100 mg ............................................................................ 30.25 PARACETAMOL ( subsidy) ❋ Oral liq 120 mg per 5ml ............................................................ 6.80 ❋ Oral liq 250 mg per 5 ml ............................................................ 7.00 TOPIRAMATE ( subsidy) ▲ Tab 25 mg .............................................................................. 26.04 ▲ Tab 50 mg .............................................................................. 44.26 ▲ Tab 100 mg ............................................................................ 75.25 ▲ Tab 200 mg .......................................................................... 129.85 ▲ Sprinkle cap 15 mg ................................................................. 20.84 ▲ Sprinkle cap 25 mg ................................................................. 26.04 LITHIUM CARBONATE ( subsidy) Tab long–acting 400 mg .......................................................... 16.05 RISPERIDONE ( subsidy) Tab 0.5 mg ............................................................................... 5.20 Tab 1 mg ................................................................................ 30.77 Tab 2 mg ................................................................................ 61.53 Tab 3 mg ................................................................................ 92.32 Tab 4 mg .............................................................................. 123.05 CALCIUM FOLINATE ( subsidy) Inj 1 mg for ECP – PCT only – Specialist .................................... 0.10 FLUDARABINE PHOSPHATE – PCT only – Specialist ( subsidy) Tab 10 mg ............................................................................ 650.25 FLUDARABINE PHOSPHATE – PCT only – Specialist ( subsidy) Inj 50 mg ............................................................................ 1430.00 METHOTREXATE – PCT – Hospital pharmacy [HP1] – Specialist ( subsidy) Inj 100 mg per ml, 10 ml – PCT Only – Specialist .................... 27.50 Inj 100 mg per ml, 50 ml – PCT Only – Specialist .................. 135.00 POLYVINYL ALCOHOL ( subsidy) ❋ Eye drops 1.4% ........................................................................ 2.68 ❋ Eye drops 3% ........................................................................... 3.75

100 5

Phosphate-Sandoz

Regitine 100 100 1,000 ml 1,000 ml 60 60 60 60 60 60 100 20 60 60 60 60 1 mg 15 5 1 1

✔ Nifuran ✔ Nifuran ✔ Junior Parapaed ✔ Six Plus Parapaed

107

114

✔ Topamax ✔ Topamax ✔ Topamax ✔ Topamax ✔ Topamax ✔ Topamax

119 120

✔ Priadel

✔ Risperdal ✔ Risperdal ✔ Risperdal ✔ Risperdal ✔ Risperdal

131 132 132 133

✔ Baxter

✔ Fludara

✔ Fludara ✔ Methotrexate Ebewe ✔ Methotrexate Ebewe ✔ Vistil ✔ Vistil Forte

154

15 ml OP 15 ml OP

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to Brand Name

Effective 1 October 2008

91 BENZYLPENICILLIN SODIUM (PENICILLIN G) Inj 1 mega u – Up to 5 inj available on a PSO ............................. 6.99 10 ✔ Sandoz ✔ Novartis

Effective 1 September 2008

43 ERYTHROPOIETIN BETA – Special Authority SA0922 – Hospital pharmacy [HP3) Inj 2,000 iu pre-filled syringe ................................................. 152.04 6 Inj 3,000 iu pre-filled syringe ................................................. 228.06 Inj 4,000 iu pre-filled syringe ................................................. 304.08 Inj 5,000 iu pre-filled syring ................................................... 380.10 Inj 6,000 iu pre-filled syringe ................................................. 456.12 Inj 10,000 iu pre-filled syringe ............................................... 760.20 6 6 6 6 6 ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon ✔ NeoRecormon Recormon

Changes to Description

Effective 1 October 2008

152 PEAK FLOW METER Peak flow meters-low range Low range Peak flow meters-normal range Normal range SPACER DEVICES AND MASKS Spacer device 230 ml (autoclavable) SPACER DEVICES AND MASK FOR SPACER DEVICE Mask, size 2 Size 2

153 153

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Changes to General Rules

Effective 1 September 2008

12 “Authority to Substitute” means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule. 4.7 Substitution Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer’s Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, subject to: a) the Contractor having received a general Authority to Substitute from the Practitioner in relation to the particular medicine or medicines in general; or b) the Practitioner having indicated their Authority to Substitute on the prescription; or c) the Practitioner having given their Authority to Substitute in relation to the particular prescription. Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and initial the prescription. 4.8 Alteration to Presentation of Pharmaceutical Dispensed A Contractor, when dispensing a Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed but may not alter the total daily dose. If the change will result in additional cost to the DHBs, then: a) the Practitioner must authorise and initial the alteration; or b) in cases where PHARMAC has approved and notified in writing such a change in dispensing of a named Pharmaceutical due to an out of stock event or short supply, the Contractor must annotate and initial the alteration. 4.9 4.7 Amendment of the Schedule PHARMAC may amend the terms of the Schedule from time to time by notice in writing given in such manner as PHARMAC thinks fit, and in accordance with such protocols as agreed with the Pharmacy Guild of New Zealand (inc) from time to time. 4.10 4.8 Conflict of Provisions If any rules in Sections B-G of this Schedule conflict with the rules in Section A, the rules in Sections B-G apply.

Changes to Sole Subsidised Supply

Effective 1 October 2008

For the list of new Sole Subsidised Supply products effective 1 October 2008 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 7-13.

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Delisted Items

Effective 1 October 2008

106 NEFOPAM HYDROCHLORIDE Inj 20 mg per ml, 1 ml .............................................................. 9.10 (72.50) PACLITAXEL – PCT only – Specialist Inj 30 mg ................................................................................ 90.00 Inj 100 mg ............................................................................ 299.70 SALBUTAMOL Tab long-acting 8 mg ............................................................. 15.30 5 Acupan 1 1 56 ✔ Taxol ✔ Taxol ✔ Volmax

136

150 180

GLUTEN FREE PASTA – Special Authority see SA0722 – Hospital pharmacy [HP3] Tomato and Basil Spirals .......................................................... 2.00 250 g OP (2.63)

Orgran

Effective 1 September 2008

37 ASCORBIC ACID AND SODIUM ASCORBATE a) No more than 100 mg per dose b) Only on a prescription ❋ Tab 100 mg ............................................................................. 2.60 PERMETHRIN Lotion 5% .................................................................................. 4.50 (7.00) ECONAZOLE NITRATE Pessaries 150 mg with applicators ........................................... 2.75 (9.71) BENZATHINE BENZYLPENICILLIN Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO........... 16.00 160 Note: Bicillin LA continues to be listed fully subsidised ACICLOVIR ❋ Tab 200 mg ............................................................................. 7.92 ❋ Tab 400 mg ........................................................................... 11.86 SAQUINAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Cap 200 mg ......................................................................... 271.00

100 50 ml OP

✔ Healtheries Vitamin C

Quellada-P 3 Pevaryl Ovules 1 10 ✔ Bicillin ✔ Bicillin

95 99 106 170

100 100 180

✔ Apo-Acyclovir ✔ Apo-Acyclovir ✔ Fortovase

ASPIRIN ❋ Tab dispersible 300 mg – Up to 30 tab available on a PSO ...... 21.50 (22.50) 1000 Ethics Aspirin ❋ Tab EC 650 mg ........................................................................ 6.88 100 ✔ Ecotrin Note: the 100 tablet pack of Ethics Aspirin, tab dispersible 300 mg will continue to be listed fully subsidised ORAL SUPPLEMENT 1KCAL/ML – Special Authority see SA0583 – Hospital pharmacy [HP3] Powder (vanilla) sachet 54 g ..................................................... 6.91 10 OP ✔ Fortisip Powder ❋ Three months or six months, as applicable, dispensed all-at-once

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted

Effective 1 December 2008

38 38 38 CALCIUM ❋ Tab eff 1 g................................................................................. 6.54 CALCIUM CARBONATE ❋ Tab dispersible 2.5 g ................................................................. 4.36 (4.98) IRON POLYMALTOSE Inj 50 mg per ml, 2 ml ............................................................. 20.95 (29.95) ZINC AND CASTOR OIL Ointment BP .............................................................................. 5.11 PARACETAMOL ❋‡ Oral liq 120 mg per 5 ml ....................................................... 6.80 a) Up to 200 ml available on a PSO b) Not in combination ❋‡ Oral liq 250 mg per 5 ml ....................................................... 7.00 30 ✔ Calcium-Sandoz 1000

20 OP Calci-Tab Effervescent 5 Ferrosig 500 g 1,000 ml 1,000 ml ✔ Multichem ✔ Junior Parapaed ✔ Six Plus Parapaed

66 107

Effective 1 January 2009

70 KETOCONAZOLE Shampoo 2% ............................................................................ 3.48 a) Maximum of 100 ml per prescription b) Only on a prescription 100 ml OP ✔ Ketopine

Effective 1 March 2009

43 47 54 56 59 ERYTHROPOIETIN BETA – Special Authority see SA0922 – Hospital pharmacy [HP3] Inj 1,000 iu, pre-filled syringe ................................................. 76.02 6 HEPARINISED SALINE ❋ Inj 100 iu per ml, 5 ml .......................................................... 103.76 LOSARTAN ❋ Tab 25 mg .............................................................................. 20.31 ATENOLOL ❋ Tab 50 mg ............................................................................... 6.50 ❋ Tab 100 mg ........................................................................... 11.30 VERAPAMIL HYDROCHLORIDE ❋ Tab 40 mg ................................................................................ 4.75 50 28 500 500 100 ✔ Recormon ✔ Mayne ✔ Cozaar ✔ Loten ✔ Loten ✔ Verpamil

Patients pay a manufacturer’s surcharge when the Manufacturer’s Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29 ‡ safety cap reimbursed Sole Subsidised Supply

Check your Schedule for full details Schedule page ref

Subsidy (Mnfr’s price) $

Per

Brand or Generic Mnfr ✔ fully subsidised

Items to be Delisted - effective 1 March 2009 (continued)

61 NICOTINE – Only on a Quitcard Gum 2 mg (Fruit) .................................................................... 23.41 Gum 2 mg (Mint) .................................................................... 23.41 Gum 4 mg (Fruit) ..................................................................... 23.41 Gum 4 mg (Mint)..................................................................... 23.41 ERYTHROMYCIN LACTOBIONATE Inj 300 mg ............................................................................. 70.97 SAQUINAVIR – Special Authority see SA0779 – Hospital pharmacy [HP1] Cap 200 mg .......................................................................... 519.75 AMITRIPTYLINE Tab 10 mg ................................................................................ 3.00 NITRAZEPAM – Month Restriction Tab 5 mg .................................................................................. 2.00 (3.90) SALBUTAMOL Tab long-acting 4 mg .............................................................. 11.18 DIBROMOPROPAMIDINE ISETHIONATE ❋ Eye oint 0.15% ......................................................................... 2.97 (7.99) 96 96 96 96 5 270 100 100 Insoma 56 5 g OP Brolene ✔ Volmax ✔ Nicotinell ✔ Nicotinell ✔ Nicotinell ✔ Nicotinell ✔ Mayne ✔ Invirase ✔ Amitrip

90 99 109 125

150 154

Effective 1 April 2009

109 182 DOXEPIN HYDROCHLORIDE Cap 75 mg ............................................................................. 10.99 100 ✔ Anten

PHENYL FREE PASTA – Special Authority see SA0733 – Hospital pharmacy [HP3] Macaroni ................................................................................. 10.65 500 g OP (11.91)

Loprofin

▲

Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

❋ Three months or six months, as applicable, dispensed all-at-once

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H changes to Part II

Effective 1 October 2008

ACETAZOLAMIDE (new listing) Tab 250 mg....................................Diamox AMITRIPTYLINE (delisting) Tab 10 mg .....................................Amitrip ATROPINE SULPHATE ( price and addition of HSS) Eye drops 1% .................................Atropt 10.40 3.00 4.40 100 100 15 ml 1% Dec-08 (B) 1% Dec-08 (B)

BENZYLPENICILLIN SODIUM (amended brand name,  price and addition of HSS) Inj 1 mega u ...................................Novartis Sandoz 10.49 10 1% Dec-08 Benpen Please note that the Benpen brand of benzylpenicillin sodium inj 1 mega u will be delisted from 1 December 2008 BEZAFIBRATE (addition of HSS) Tab 200 mg....................................Fibalip CALCITONIN (new listing) Inj 100 u per ml, 1 ml .....................Miacalcic 9.75 110.00 90 5 1% 1% Dec-08 Dec-08 (B) (B)

CEFAZOLIN SODIUM (new listing) Inj 500 mg .....................................Hospira 5.00 5 1% Dec-08 m-Cefazolin Inj 1 g.............................................Hospira 8.00 5 1% Dec-08 m-Cefazolin Please note that the m-Cefazolin brand of cefazolin injections 500 mg and 1 g will be delisted from 1 December 2008 CLONAZEPAM (new listing) Tab 500 mcg ..................................Paxam Tab 2 mg........................................Paxam CLOZAPINE (new listing) Tab 25 mg......................................Clopine Tab 50 mg......................................Clopine Tab 100 mg....................................Clopine Tab 200 mg....................................Clopine ERYTHROMYCIN ETHYL SUCCINATE (new listing) Grans for oral liq 200 mg per 5 ml ..E-Mycin Grans for oral liq 400 mg per 5 ml ..E-Mycin FINASTERIDE (new listing and addition of HSS) Tab 5 mg........................................Fintral 6.26 11.15 35.20 45.60 91.20 145.92 4.35 5.85 19.20 100 100 100 100 100 100 100 ml 100 ml 30 1% 1% 1% (B) (B) Dec-08 Proscar 1% 1% Dec-08 Dec-08 (B) (B)

FLUCLOXACILLIN SODIUM (addition of HSS) Inj 250 mg......................................Flucloxin 9.00 10 1% Feb-09 Floxapen Inj 500 mg......................................Flucloxin 10.40 10 1% Feb-09 Floxapen Inj 1 g ............................................Flucloxin 14.00 10 1% Feb-09 Floxapen Please note the 5 pack of Flucloxin brand of flucloxacillin injection 250 mg, 500 mg and 1 g will be delisted from 1 December 2008 HYOSCINE N-BUTYLBROMIDE ( price and addition of HSS) Inj 20 mg per ml, 1ml .....................Buscopan 8.04 Products with Hospital Supply Status (HSS) are in bold. 5 1% Dec-08 (B)

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 October 2008 (continued)

HYOSCINE N-BUTYLBROMIDE (new listing) Tab 10 mg......................................Gastrosoothe MEBEVERINE HYDROCHLORIDE (new listing) Tab 135 mg....................................Colofac METHYLDOPA (new listing) Tab 125 mg....................................Prodopa Tab 250 mg....................................Prodopa Tab 500 mg....................................Prodopa NORTRIPTYLINE HYDROCHLORIDE (new listing) Tab 10 mg......................................Norpress Tab 25 mg......................................Norpress NYSTATIN (addition of HSS) Oral liquid 100,000 u per ml ...........Nilstat POLOXAMER (new listing) Oral drops 10% ..............................Coloxyl 1.62 18.00 12.00 13.10 20.85 5.94 20.06 3.19 3.78 20 90 100 100 100 100 250 24 ml 30 ml 500 500 500 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% 1% Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Buscopan (B) (B) (B) (B) (B) (B) (B) (B) Douglas Origen Douglas Origen Douglas Origen (B)

PREDNISONE (new listing) Tab 1 mg........................................Apo-Prednisone 10.68 Tab 2.5 mg.....................................Apo-Prednisone 12.09 Tab 5 mg........................................Apo-Prednisone 11.09 PROCAINE PENICILLIN ( price and addition of HSS) Inj 1.5 mega u ................................Cilicaine RISPERIDONE (new listing) Tab 0.5 mg.....................................Ridal SALBUTAMOL (removal of DV pharmaceutical) Nebuliser soln 1 mg per ml, 2.5 ml .Asthalin SIMVASTATIN (new listing) Tab 80 mg .....................................SimvaRex STREPTOKINASE ( price and addition of HSS) Inj 250,000 IU ................................Streptase Inj 1,500,000 IU .............................Streptase

50.86 15.60 3.70

5 60 20

Dec-08

July-07

Ventolin nebules (B)

3.18 117.70 188.10

30 1 1 1% 1% Dec-08 Dec-08 (B) (B)

TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUORESCEIN (new listing) Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium ......................................Pinetarsol 2.90 500 ml 1% Pinetarsol 5.45 1000 ml Products with Hospital Supply Status (HSS) are in bold.

Dec-08

(B)

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 October 2008 (continued)

TEMAZEPAM (new listing) Tab 10 mg......................................Normison TERLIPRESSIN (new listing) Inj 1 mg..........................................Glypressin TRIAMCINOLONE ACETONIDE (new listing) Crm 0.02% .....................................Aristocort Oint 0.02% .....................................Aristocort TRIAMCINOLONE ACETONIDE (addition of HSS) Inj 40 mg per ml, 1 ml ....................Kenacort-A40 TRIMETHOPRIM (new listing) Tab 300 mg....................................TMP 0.83 450.00 6.63 6.69 28.09 8.69 25 5 100 g 100 g 5 50 1 100 1% 1% 1% 1% 1% 1% 1% 1% Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 Dec-08 (B) (B) (B) (B) Baxter (B) Hospira (B)

VANCOMYCIN HYDROCHLORIDE ( price and addition of HSS) Inj 50 mg per ml, 10 ml .................Pacific 5.04 ZINC SULPHATE (new listing) Cap 220 mg ...................................Zincaps 10.00

Effective 1 September 2008

AMANTADINE HYDROCHLORIDE Cap 100 mg ...................................Symmetrel AMITRIPTYLINE Tab 10 mg......................................Amirol ATENOLOL Tab 50 mg......................................Pacific Atenolol Tab 50 mg......................................Loten Tab 100 mg ...................................Pacific Atenolol 47.81 2.77 6.50 60 50 500 1% Sept-06 Anselol Apo-Atenolol Golbal Atenolol Anselol Apo-Atenolol Golbal Atenolol 1% Oct-08 (B)

11.30

500

Sept-06

Tab 100 mg....................................Loten Please note that the Loten brand of atenolol tablets 50 mg and 100 mg will be delisted from 1 September 2008. AQUEOUS (new listing) Cream ............................................AFT 1.49 100 g 1% Nov 08 Orion Multichem PSM

Note – Multichem brand of aqueous cream 100 g will be delisted from 1 November 2008 DV limit applies to pack sizes of 100 g or less CLOPIDOGREL (new listing) Tab 75 mg......................................Apo-Clopidogrel 35.00 28

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 September 2008 (continued)

DIPYRIDAMOLE Tab long-acting 150 mg..................Pytazen SR EMULSIFYING OINTMENT (new listing) Ointment BP ...................................AFT ERYTHROPOIETIN ALPHA (new listing) Inj human recombinant 1,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 2,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 3,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 4,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 5,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 6,000 iu, pre-filled syringe ........................Eprex Inj human recombinant 10,000 iu, pre-filled syringe ........................Eprex ERYTHROPOIETIN BETA (change to brand name) Inj 2,000 iu prefilled syringe ............NeoRecormon Recormon Inj 3,000 iu prefilled syringe ............NeoRecormon Recormon Inj 4,000 iu prefilled syringe ............NeoRecormon Recormon Inj 5,000 iu prefilled syringe ............NeoRecormon Recormon Inj 6,000 iu prefilled syringe ............NeoRecormon Recormon Inj 10,000 iu prefilled syringe ..........NeoRecormon Recormon FLUDARABINE ( price) Tab 10 mg......................................Fludara FLUDARABINE PHOSPHATE ( price) Inj 50 mg........................................Fludara IMIQUIMOD (new listing) Cream 5 %, sachet .........................Aldara INSULIN GLARGINE Inj 100 iu per ml, 3 ml ....................Lantus SoloStar 11.52 2.50 60 100 g 1% 1% Oct-08 Nov 08 Persantin (B)

48.68 120.18 166.87 193.13 243.26 291.92 395.18 152.04 228.06 304.08 380.10 456.12 760.20

6 6 6 6 6 6 6 6 6 6 6 6 6 5% 5% 5% 5% 5% 5% Apr-06 Apr-06 Apr-06 Apr-06 Apr-06 Apr-06 (B) (B) (B) (B) (B) (B)

650.25 1430.00 110.40 94.50

15 5 12 5

1% 1%

Nov 08 Nov 08

(B) (B)

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 September 2008 (continued)

METHOTREXATE ( price and HSS addition) Inj 100 mg per ml, 10 ml ................Methotrexate Ebewe Inj 100 mg per ml, 50 ml ................Methotrexate Ebewe 27.50 135.00 1 1 1% 1% Nov-08 Nov-08 Hospira Hospira

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE (new listing) Tablet extended-release 18 mg .......Concerta 58.96 30 Tablet extended-release 27 mg .......Concerta 65.44 30 Tablet extended-release 36 mg .......Concerta 71.93 30 Tablet extended-release 54 mg .......Concerta 86.24 30 NICOTINE Lozenge 1 mg ................................Habitrol Lozenge 2 mg ................................Habitrol PRILOCAINE HYDROCHLORIDE Inj 0.5%, 50 ml ...............................Citanest Inj 0.5%, 50 ml ...............................Citanest RISPERIDONE ( price) Tab 0.5 mg.....................................Risperdal Tab 1 mg........................................Risperdal Tab 2 mg........................................Risperdal Tab 3 mg........................................Risperdal Tab 4 mg........................................Risperdal SODIUM CHLORIDE (new listing) Soln 0.9% for irrigation ...................Pfizer TOPIRAMATE (new listing) Tab 25 mg......................................Topamax Tab 50 mg......................................Topamax Tab 100mg.....................................Topamax Tab 200mg.....................................Topamax Sprinkle cap 15 mg.........................Topamax Sprinkle cap 25 mg.........................Topamax 11.08 11.08 80.00 160 5.20 30.77 61.53 92.32 123.05 20.00 26.04 44.26 75.25 129.85 20.84 26.04 36 36 5 10 20 60 60 60 60 30 ml 60 60 60 60 60 60 1% Nov 08 Orion

Effective 1 August 2008

ADALIMUMAB (new listing) Inj 40 mg per 0.8 ml prefilled pen ...............................HumiraPen

1,799.92

2 Oct-08 Oct-08 Oct-08 AFT AFT AFT

CEFOTAXIME (new listing) Inj 500 mg......................................Cefotaxime Sandoz 1.69 1 1% Inj 1 g.............................................Cefotaxime Sandoz 1.90 1 1% Inj 2 g.............................................Cefotaxime Sandoz 2.60 1 1% Note - AFT brand of cefotaxime inj, 1 g & 2 g will be delisted 1 October 2008.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description

Brand

Price ($) (ex man. excl. GST)

Per

DV Limit

DV Limit DV applies Pharmaceutical from

Section H - effective 1 August 2008 (continued)

GLYCERYL TRINITRATE Tab 600 µg ....................................Lycinate IVERMECTIN (new listing) Tab 3 mg........................................Stromectol KETOCONAZOLE (new listing) Shampoo 2 % .................................Sebizole METHOTREXATE Inj 100 mg per ml, 5 ml ..................Methotrexate Ebewe METRONIDAZOLE Suppos 1 g.....................................Flagyl 8.00 25.96 3.48 100 4 100 ml 1% 1% 1% Sept-08 Oct-08 Oct-08 (B) (B) Ketopine Nizoral

18.00

33.31

10 1 1 1 1 1 1% 1% 1% 1% 1% Oct-08 Oct-08 Oct-08 Oct-08 Oct-08 Anzatax Taxol Anzatax Taxol (B) Anzatax Taxol Anzatax Taxol

PACLITAXEL (new listing) Inj 30 mg .......................................Paclitaxel Ebewe 37.95 Inj 100 mg......................................Paclitaxel Ebewe125.35 Inj 600 mg......................................Paclitaxel Ebewe724.50 PACLITAXEL ( price and addition of HSS) Inj 150 mg......................................Paclitaxel Ebewe188.03 Inj 300 mg......................................Paclitaxel Ebewe376.05

Note - The Taxol brand of paclitaxel inj 150 mg & 300 mg will be delisted from 1 October 2008.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Chemical and presentation

Brand

Section H changes to Part IV

Effective 1 October 2008

CHLORHEXADINE Eye drops 0.02% For a period of 3 months for treatment of acanthamoeba keratitis. ONDANSETRON HYDROCHLORIDE Tab 4 mg Zofran Tab 8 mg Zofran Tab dispersible 4 mg Zofran Zydis Tab dispersible 8 mg Zofran Zydis For treatment of patients with hyperemesis gravidarum for the term of the pregnancy following failure of other antiemetic regimens. POLYHEXAMETHYLENE BIGUANIDE Eye drops 0.02% For a period of 3 months for treatment of acanthamoeba keratitis. PYRIMETHAMINE Tab 25 mg (Section 29) For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; For pregnant patients for the term of the pregnancy; For infants with congenital toxoplasmosis until 12 months of age. SULPHADIAZINE Tab 500 mg (Section 29) For the treatment of toxoplasmosis in patients with HIV for a period of 3 months; For pregnant patients for the term of the pregnancy; For infants with congenital toxoplasmosis until 12 months of age.

Effective 1 September 2008

CEFUROXIME AXETIL Tab 250 mg Oral liq 125 mg per 5 ml Up to 2 weeks supply for any appropriate indication CEFUROXIME SODIUM Tab 250 mg Oral liq 125 mg per 5 ml Up to 2 weeks supply for any appropriate indication Inj 250 mg Inj 750 mg Inj 1.5 g For any indication approved by the hospital service, with review at 6 weeks.

Products with Hospital Supply Status (HSS) are in bold.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Index

Pharmaceuticals and brands A Acarbose ........................................................... 17 Acetazolamide ............................................. 23, 30 Aciclovir ............................................................ 27 Acupan .............................................................. 27 Adalimumab....................................................... 34 Aldara .......................................................... 15, 33 Amantadine hydrochloride .................................. 32 Aminoacid formula without phenylalanine ..... 14, 23 Amirol .......................................................... 16, 32 Amitrip ......................................................... 29, 30 Amitriptyline ..................................... 16, 29, 30, 32 Anten ................................................................. 29 Apo-Acyclovir .................................................... 27 Apo-Clopidogrel ........................................... 15, 32 Apo-Prednisone ........................................... 22, 31 Aqueous ............................................................ 32 Aristocort ..................................................... 21, 32 Ascorbic acid and sodium ascorbate .................. 27 Aspirin ............................................................... 27 Asthalin ............................................................. 31 Atenolol ................................................. 15, 28, 32 Atropine sulphate ......................................... 23, 30 Atropt .......................................................... 23, 30 B Benzathine benzylpenicillin ................................. 27 Benzylpenicillin sodium ...................................... 30 Benzylpenicillin sodium (penicillin G) ............ 22, 25 Bezafibrate ................................................... 21, 30 Bicillin ................................................................ 27 Breath-Alert........................................................ 23 Brolene .............................................................. 29 Buscopan .................................................... 21, 30 C Calcitonin..................................................... 22, 30 Calcium ............................................................. 28 Calci-Tab Effervescent ................................. 23, 28 Calcium-Sandoz 1000 ........................................ 28 Calcium carbonate ....................................... 23, 28 Calcium folinate ................................................. 24 Cefazolin sodium ......................................... 14, 30 Cefotaxime......................................................... 34 Cefotaxime Sandoz ............................................ 34 Cefuroxime axetil................................................ 36 Cefuroxime sodium ............................................ 36 Chlorhexadine .................................................... 36 Cilicaine ....................................................... 22, 31 Citanest ............................................................. 34 Clonazepam ................................................. 22, 30 Clopidogrel ............................................ 15, 21, 32 Clopine ........................................................ 14, 30 Clozapine ..................................................... 14, 30 Colofac ........................................................ 21, 31 Coloxyl ........................................................ 21, 31 Concerta ...................................................... 16, 34 Cozaar ......................................................... 15, 28 D Depo-Provera ..................................................... 16 Diastop .............................................................. 17 Diphenoxylate hydrochloride with atropine sulphate............................................. 17 Diamox ........................................................ 23, 30 Dibromopropamidine isethionate ........................ 29 Dipyridamole...................................................... 33 Doxepin hydrochloride........................................ 29 DP Lotion ........................................................... 21 E Easiphen ............................................................ 23 Easiphen Liquid.................................................. 23 Econazole nitrate ................................................ 27 Ecotrin ............................................................... 27 Emulsifying ointment .......................................... 33 E-Mycin ....................................................... 22, 30 Eprex ..................................................... 15, 23, 33 Erythromycin ethyl succinate ........................ 22, 30 Erythromycin lactobionate .................................. 29 Erythropoietin alpha.......................... 15, 17, 23, 33 Erythropoietin beta ................................. 25, 28, 33 Ethics Aspirin ..................................................... 27 F Ferrosig ....................................................... 23, 28 Fibalip .......................................................... 21, 30 Finasteride ................................................... 14, 30 Fintral .......................................................... 14, 30 Flagyl ................................................................. 35 Flucloxacillin sodium .................................... 14, 30 Flucloxin ...................................................... 14, 30 Fludara......................................................... 24, 33 Fludarabine ........................................................ 33 Fludarabine phosphate ................................. 24, 33 Foremount Child’s Silicone Mask ........................ 23 Fortisip Powder .................................................. 27 Fortovase ........................................................... 27 G Gastrosoothe ............................................... 21, 31 Genotropin ......................................................... 18 Glucobay ........................................................... 17 Gluten free pasta ................................................ 27 Glyceryl trinitrate ................................................ 35 Glypressin.......................................................... 32 Growth hormone biosynthetic human ................. 18 H Habitrol ........................................................ 15, 34 Healtheries Vitamin C ......................................... 27

Index

Pharmaceuticals and brands Heparinised saline .............................................. 28 Heparin sodium.................................................. 21 HumiraPen ......................................................... 34 Hyoscine N-butylbromide ....................... 21, 30, 31 Hypnovel ........................................................... 22 I Imiquimod ................................................... 15, 33 Insoma .............................................................. 29 Insulin glargine ............................................. 15, 33 Invirase .............................................................. 29 Iron polymaltose .......................................... 23, 28 Ivermectin .......................................................... 35 J Junior Parapaed ........................................... 24, 28 K Kenacort-A40..................................................... 32 Ketoconazole ......................................... 22, 28, 35 Ketopine ...................................................... 22, 28 L Lantus SoloStar ........................................... 15, 33 Lithium carbonate .............................................. 24 Lophlex LQ......................................................... 14 Loprofin ....................................................... 14, 29 Losartan ...................................................... 15, 28 Loten ........................................................... 28, 32 Lycinate ............................................................. 35 M Mask for spacer device ................................ 23, 25 Mebeverine hydrochloride ............................ 21, 31 Medroxyprogesterone acetate............................. 16 Methadone hydrochloride ................................... 17 Methotrexate .......................................... 24, 34, 35 Methotrexate Ebewe ............................... 24, 34, 35 Methyldopa .................................................. 21, 31 Methylphenidate hydrochloride ........................... 20 Methylphenidate hydrochloride extended-release ....................................... 16, 34 Metronidazole .................................................... 35 Miacalcic ..................................................... 22, 30 Midazolam ......................................................... 22 Minaphlex .......................................................... 23 N Nefopam hydrochloride ...................................... 27 NeoRecormon .............................................. 25, 33 Nicotine ................................................. 15, 29, 34 Nicotinell ............................................................ 29 Nifuran ............................................................... 24 Nilstat .......................................................... 21, 31 Nitrazepam......................................................... 29 Nitrofurantoin ..................................................... 24 Norditropin SimpleXx 5mg .................................. 18 Norditropin SimpleXx 10mg ................................ 18 Norditropin SimpleXx 15mg ................................ 18 Normison ..................................................... 22, 32 Norpress ...................................................... 22, 31 Nortriptyline hydrochloride............................ 22, 31 Nystatin ....................................................... 21, 31 O Ondansetron hydrochloride................................. 36 Oral supplement 1kcal/ml ................................... 27 Orgran ............................................................... 27 P Pacific Atenolol ............................................ 15, 32 Paclitaxel ............................................... 22, 27, 35 Paclitaxel Ebewe ................................................ 35 Paediatric oral feed 1kcal/ml............................... 14 Paracetamol................................................. 24, 28 Paxam ......................................................... 22, 30 Peak flow meter ........................................... 23, 25 Pediasure........................................................... 14 Permethrin ......................................................... 27 Pevaryl Ovules ................................................... 27 Phentolamine mesylate ...................................... 24 Phenyl free pasta ......................................... 14, 29 Phlexy 10........................................................... 23 Phosphate-Sandoz ....................................... 21, 24 Pinetarsol..................................................... 21, 31 Plavix ................................................................. 21 Poloxamer ................................................... 21, 31 Polyhexamethylene biguanide ............................. 36 Polyvinyl alcohol ................................................ 24 Potassium bicarbonate ................................. 21, 24 Prednisone................................................... 22, 31 Priadel ............................................................... 24 Prilocaine hydrochloride ..................................... 34 Procaine penicillin ........................................ 22, 31 Prodopa ....................................................... 21, 31 Pyrimethamine ................................................... 36 Pytazen SR ........................................................ 33 Q Quellada-P ......................................................... 27 R Recombinant human growth hormone ................ 18 Recormon .............................................. 25, 28, 33 Regitine ............................................................. 24 Ridal ...................................................... 14, 19, 31 Risperdal ......................................... 17, 19, 24, 34 Risperdal Consta .......................................... 17, 19 Risperdal Quicklet .............................................. 20 Risperidone.................... 14, 17, 19, 20, 24, 31, 34 Rubifen .............................................................. 20 Rubifen SR ........................................................ 20

Index

Pharmaceuticals and brands S Salbutamol............................................. 27, 29, 31 Saquinavir .................................................... 27, 29 Sebizole ............................................................. 35 SimvaRex .................................................... 14, 31 Simvastatin .................................................. 14, 31 Six Plus Parapaed ........................................ 24, 28 Sodium chloride ................................................. 34 Space Chamber ................................................. 23 Spacer device .............................................. 23, 25 Spacer devices and masks ................................. 25 Streptase ........................................................... 31 Streptokinase ..................................................... 31 Stromectol ......................................................... 35 Sulphadiazine ..................................................... 36 Symmetrel ......................................................... 32 T Tar with triethanolamine lauryl sulphate and fluorescein ................................................ 21, 31 Taxol ................................................................. 27 Temazepam ................................................. 22, 32 Terlipressin ........................................................ 32 TMP............................................................. 22, 32 Topamax...................................................... 24, 34 Topiramate............................................. 19, 24, 34 Triamcinolone acetonide .............................. 21, 32 Trimethoprim ............................................... 22, 32 V Vancomycin hydrochloride ........................... 22, 32 Verapamil hydrochloride ..................................... 28 Verpamil ............................................................ 28 Vistil .................................................................. 24 Vistil Forte .......................................................... 24 Volmax ........................................................ 27, 29 W Wool fat with mineral oil ..................................... 21 X XP Analog LCP ................................................... 23 XP Maxamaid ..................................................... 23 XP Maxamum .................................................... 23 Z Zinc and castor oil .............................................. 28 Zincaps ........................................................ 21, 32 Zinc sulphate................................................ 21, 32 Zofran ................................................................ 36 Zofran Zydis ....................................................... 36

Pharmaceutical Management Agency Level 9, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz Freephone Information line (9am-5pm weekdays) 0800 66 00 50

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the Update.

Metadata

Title

Schedule Update - effective 1 October 2008

Abstract

Pharmaceutical Management Agency Update New Zealand Pharmaceutical Schedule Effective 1 October 2008 Cumulative for September and October 2008 Section H cumulative for August, September and October 2008 Contents Summary of PHARMAC decisions effective 1 October 2008 ….. 3 New Treatment…

Page 1

Note

This text has been extracted from the source PDF document.

Also available as plain text.

Please contact webmaster to discuss alternative format options.